The causative SARS-CoV-2 virus attaches to cells by binding its outer “Spike” proteins to a receptor protein called ACE2 (angiotensin-converting enzyme 2) that is highly expressed on respiratory cells.  ACE2 also acts as the receptor for the human respiratory coronavirus NL63 and the SARS-coronavirus (SARS-CoV).  Studies have shown that the binding affinity of the virus Spike protein for ACE2 correlates with higher transmissibility of the coronavirus and contagiousness of the disease.  Angiotensin receptor blockers have been proposed as  tentative SARS-CoV-2 therapeutics.  Interestingly, ACE2 activity may also have a protective effect against virus-induced lung injury by increasing the production of the vasodilator angiotensin 1–7.

 

BPS has developed a new assay kit to screen for inhibitors of the exopeptidase activity of ACE2.  

 

ACE2 Inhibitor Screening Assay Kit        96 reactions      

https://bpsbioscience.com/ace2-inhibitor-screening-assay-kit-79923

 

We also have the recombinant ACE2 protein:    

20 ug      or  100 ug   

https://bpsbioscience.com/ace2-his-tag-11003

 

We are also actively developing an ELISA assay to measure the Spike protein binding to ACE2, and we will let you know as soon as this is available.